Mutant p53-carrying tumors are often more resistant to chemotherapeutical drugs. We demonstrate here that the mutant p53-reactivating compound PRIMA-1 MET acts synergistically with several chemotherapeutic drugs to inhibit tumor cell growth. Combined treatment with cisplatin and PRIMA-1 MET resulted in a synergistic induction of tumor cell apoptosis and inhibition of human tumor xenograft growth in vivo in SCID mice. The induction of mutant p53 levels by chemotherapeutic drugs is likely to increase the sensitivity of tumor cells to PRIMA-1 MET . Thus, the combination of PRIMA-1 MET with currently used chemotherapeutic drugs may represent a novel and more efficient therapeutic strategy for treatment of mutant p53-carrying tumors.
Introduction
The p53 tumor suppressor protein induces cell cycle arrest and/or cell death by apoptosis in response to various forms of cellular stress, for example, DNA damage and oncogene activation (Vousden and Lu, 2002) . p53 elicits these responses through transcriptional regulation of a large number of downstream effector genes. The p21, Gadd45, and 14-3-3sigma genes are effectors of p53-dependent cell cycle arrest, whereas transactivation of proapoptotic genes within the mitochondrial and death receptor pathways, including Bax, Noxa, PUMA, Fas and KILLER/DR5, promotes p53-dependent apoptotis. In addition, p53 can transrepress some genes, for instance the antiapoptotic Bcl-2 gene, the IGF1 receptor, MAP4, and hTERT (Vogelstein et al., 2000) . It is presumably the concerted action of a whole set of p53-induced genes, along with downregulation of p53-repressed genes, that triggers a specific biological response. The p53-induced MDM2 gene regulates p53 turnover via a negative feedback loop that ensures low levels of p53 in the absence of stress signaling (Michael and Oren, 2003) . Mutations in the p53 gene occur in 50% of human tumors (see http:// www.iarc.fr/p53). The great majority of these mutations are missense mutations that disrupt specific DNA binding of p53 and thus the ability of p53 to regulate transcription of target genes. Due to failure to transactivate the p53 antagonist MDM2, mutant p53 proteins are usually expressed at significantly elevated levels in tumors. The acquisition of p53 mutation is a critical step during tumor development, allowing survival and sustained growth of cells carrying activated oncogenes in a hypoxic environment.
The correlation between p53 status and response to therapy can be studied at different levels. Studies in cultured human tumor cells and various mouse tumor models have shown that inactivation of p53 reduces or abrogates the apoptotic response to chemotherapy (Bunz et al., 1999; Keshelava et al., 2001; Schmitt, 2003) . Available clinical data are somewhat contradictory, in part because the methods used for determining p53 status (immunohistochemistry, incomplete sequencing) are not accurate. Nonetheless, many studies have indicated that mutant p53-carrying tumors are indeed more resistant to chemotherapy (Bergh et al., 1995; Cadwell and Zambetti, 2001; Campling and el-Deiry, 2003) . Therefore, it is conceivable that reconstitution of wild-type p53 function could render tumor cells more responsive to chemotherapy. In recent years, a number of molecules that can reactivate mutant p53 have been identified, including short peptides (Selivanova et al., 1997; Issaeva et al., 2003) , glycerol (Ohnishi et al., 1999 (Ohnishi et al., , 2002 , ellipticine derivatives (Sugikawa et al., 1999) , CP-31398 (Foster et al., 1999) , WR1065 (North et al., 2002) , and PRIMA-1 (Bykov et al., 2002b) . This raises the possibility of combining mutant p53-reactivating molecules with chemotherapeutic drugs as a novel strategy to treat cancer. Such a strategy would potentially have greater clinical efficacy and less unwanted side effects.
Here we have tested whether PRIMA-1 MET can synergize with commonly used anticancer drugs including cisplatin (DNA alkylator), camptothecin (topoisomerase I inhibitor), adriamycin (topoisomerase II inhibitor), 5-fluorouracil (interference with RNA/DNA synthesis), paclitaxel (polymerization of cytoskeleton), and vinblastin (depolymerization of cytoskeleton) (see web site: http//dtp.nci.nih.gov) in vitro to induce cell death in human tumor cells. We demonstrate significant synergy between PRIMA-1 MET and several of these drugs in human tumor cells cultured in vitro. We also observed synergistic antitumor activity of PRIMA-1 MET and cisplatin in SCID mice carrying human tumor xenografts.
Results
Mutant p53-dependent inhibition of cell growth by PRIMA-1 and PRIMA-1
MET
We have identified several structural analogs of PRI-MA-1 that show mutant p53-dependent activity in a WST-1 proliferation assay (Bykov et al., unpublished results) . A methylated form of PRIMA-1, 2-hydroxymethyl-2-methoxymethyl-aza-bicyclo[2.2.2]octan-3-one (PRIMA-1 MET ), was more active than the original compound ( Figure 1 ). The concentration of PRIMA-1 MET required to achieve 50% growth inhibition (IC 50 ) of Saos-2 cells expressing His-273 mutant p53 was 9 mM, whereas the corresponding IC 50 value for original PRIMA-1 was 14 mM. In H1299-His175 cells, the IC 50 value was 19 mM for PRIMA-1 MET and 24 mM for original PRIMA-1. PRIMA-1 MET was twice as efficient as PRIMA-1 in inducing active caspase-3-positive cells according to FACS analysis (data not shown).
Synergy between PRIMA-1 MET and chemotherapeutic drugs in a cell proliferation assay In order to study the combined effects of PRIMA-1 MET and chemotherapeutic drugs, we treated human H1299 lung carcinoma cells expressing exogenous His175 mutant p53 with PRIMA-1 MET and cisplatin, 5-fluorouracil, camptothecin, adriamycin, vinblastin, paclitaxel or CP-31398, and assessed cell proliferation and survival using the WST-1 assay. As control, we used parental p53 null H1299 cells and H1299 His175 cells treated with doxycycline to turn off p53 His175 expression. This analysis revealed certain concentrations of PRIMA-1 MET and some of the chemotherapeutic drugs, where each drug alone had a relatively weak effect but the combination of both drugs produced a significant effect which was larger than the sum of the effects of each drug alone, indicating synergy. We observed a mutant p53-dependent synergistic effect for the combination of PRIMA-1 MET and adriamycin, cisplatin, camptothecin, or CP-31398 (Figure 2a; (Figure 2b and c) . Thus, treatment with PRIMA-1 MET enhanced the sensitivity of mutant p53-carrying tumor cells to the tested anticancer drugs.
We tested the sensitivity of wild-type p53-carrying HCT116 cells to the same panel of chemotherapeutic drugs. These cells were more sensitive to all tested Figure 1 Structural formulas of PRIMA-1 and PRIMA-1 MET and growth inhibition curves for both compounds according to the WST-1 assay 
Analysis of synergy by FACS
To confirm and extend the results obtained with the WST-1 proliferation assay, we examined the ability of cisplatin and PRIMA-1 MET alone or in combination to induce apoptosis by FACS analysis. Cells were treated with PRIMA-1 MET and cisplatin according to the protocol for the WST-1 assay. FACS profiles of propidium iodide-stained H1299 and H1299-His175 cells after treatment with PRIMA-1 MET and cisplatin are shown in Supplementary Figure 7 . Treatment of H1299-His175 cells with cisplatin (2 mg/ml) or PRIMA-1 MET (25 mM) alone caused relatively minor cell death (18 and 6% cells with sub-G 1 DNA content, respectively). However, the combination of both drugs was synergistic, resulting in 46% dead cells according to sub-G 1 DNA content. Parental p53 null H1299 cells were more sensitive to cisplatin than the mutant p53-carrying subline (37% dead cells after treatment). PRIMA-1 MET at a concentration of 25 mM did not affect growth of the H1299 cells, but the combined treatment resulted in 32% dead cells (Supplementary Figure 7) . Thus, PRIMA-1 MET and cisplatin acted synergistically to induce mutant p53-dependent apoptosis in H1299 cells. MET resulted in decreased IC 50 ratios for most of the tested drugs, and thus increases sensitivity of mutant p53-expressing cells compared to p53 nulls cells to these drugs. (d) IC 50 ratios for HCT116 cells expressing wild-type p53 and HCT116 lacking p53. In contrast to the effect on mutant p53-expressing tumor cells, PRIMA-1 MET had no significant effect on IC 50 ratios for most chemotherapeutic drugs, or even caused increased IC 50 ratios for camptothecin and vinblastin. Thus, PRIMA-1 MET did not sensitize wild-type p53-expressing cells to chemotherapeutic drugs MET induced 3% cell death, whereas the combined treatment resulted in 33% dead cells.
Synergistic induction of active caspase-positive cells in a mutant p53-dependent manner
To further investigate the synergistic effect of PRIMA-1 MET and cisplatin, we examined caspase activity in treated cells using the CaspaTag pan-caspase activity reagent as a marker for apoptosis. We treated H1299-His175 cells with 2 mg/ml of cisplatin for 24 h, added PRIMA-1 MET and incubated the cells for another 24 h. The fraction of active caspase-positive cells was then determined (Figure 3a) . Cisplatin alone induced 15% active caspase-positive cells as compared to untreated control cells, whereas PRIMA-1 MET (25 mM) alone had only a marginal effect (0.5% active caspase-positive cells). The combined treatment did not have any significantly stronger effect than cisplatin alone (17% active caspase-positive cells). Treatment with a higher dose of PRIMA-1 MET , 50mM, induced 39% active caspase-positive cells. The combination of cisplatin and 50 mM of PRIMA-1 MET had a potent apoptosisinducing effect, resulting in 73% active caspase-positive cells (Figure 3b) .
Treatment of p53 null H1299 cells with cisplatin induced 18% active caspase-positive cells, while treatment with 25 mM of PRIMA-1 MET alone did not cause any substantial caspase activation. The combined treatment caused induction of active caspases in 13% of the cells. Treatment with 50 mM of PRIMA-1 MET alone did not induce any substantial caspase activity, whereas combined treatment with cisplatin and PRIMA-1 MET produced 19% active caspase-positive H1299 cells (Figure 3b ). These results thus confirm that PRIMA-1 MET and cisplatin act synergistically to activate caspases in a mutant p53-dependent manner.
Mutant p53-dependent synergistic induction of Bax and PUMA Next, we asked if cisplatin and PRIMA-1 MET could synergize to induce expression of the proapoptotic p53 targets Bax and PUMA. We treated H1299 and H1299-His175 cells with 2 mg/ml of cisplatin for 24 h, added PRIMA-1 MET and continued incubation for 16 h, and then assessed Bax expression by immunostaining and FACS analysis or PUMA expression by Western blotting. Treatment of H1299-His175 cells with cisplatin or PRIMA-1 MET (25 mM) alone caused only a small increase in the fraction of Bax-positive cells (10 and 8%, respectively), whereas the combination of both drugs produced a significantly increased fraction of Baxpositive cells, 48% (Figure 4a and b) . In the p53 null H1299 cells, treatment with both drugs did not induce any further increase in Bax-positive cells than cisplatin alone. As shown in Figure 4c , the combination treatment resulted in a synergistic increase in the levels of PUMA protein expression in a mutant p53-dependent manner. Thus, cisplatin and PRIMA-1 MET act synergistically to induce both Bax and PUMA, but only in the presence of mutant p53.
Synergistic growth suppression by PRIMA-1 MET and cisplatin in a colony formation assay
We also examined the effect of combined treatment with PRIMA-1
MET and cisplatin in a colony formation assay, MET alone or in combination and cultured in flasks. Colonies were counted after 10 days. For H1299 cells lacking p53, cisplatin (1 mg/ml) treatment resulted in 21.4% suppression of colony formation, whereas 20 mM of PRIMA-1 MET had almost no effect (0.2% suppression). The combined treatment caused a significant suppression of colony formation (54.4%). We also treated H1299-His175 cells cultured in the presence of doxycycline to switch off mutant p53. Cisplatin induced 11.2% suppression of colony formation in these cells. Again, PRIMA-1 MET alone had little effect (0.1%), while treatment with both drugs together reduced the number of colonies by 17.2%. H1299-His175 cells expressing His175 mutant p53 were moderately sensitive to either cisplatin (27% suppression) or PRIMA-1 MET (27.1% suppression) alone, but in contrast to what we observed in the same cells in the presence of doxycycline that suppresses mutant p53 expression, the combination of cisplatin with PRIMA-1 MET caused a marked reduction in number of colonies (85.6%) (Supplementary Figure 8) . We conclude that cisplatin and PRIMA-1 MET act synergistically to inhibit colony formation in H1299 cells, particularly in the presence of mutant p53.
Synergy between cisplatin and PRIMA-1 MET in SCID mice carrying H1299-His175 tumor xenografts
To determine whether PRIMA-1 MET and cisplatin could act synergistically to inhibit tumor growth in vivo, we inoculated SCID mice with H1299-His175 cells and treated them with PRIMA-1 MET alone or in combination with different concentrations of cisplatin. We used doses of cisplatin and PRIMA-1 MET that alone did not cause any major inhibition of xenograft tumor growth. The treatment did not cause any changes in behavior nor weight loss in the mice. The average tumor volume in control animals treated with PBS was 1130 mm 3 after 34 days and the average tumor volume in mice that received 100 mg/kg of PRIMA-1 MET was 840 mm 3 . Treatment with cisplatin at a dose of 0.25 or 1 mg/kg resulted in average tumor volumes of 680 and 992 mm 3 , respectively. The combination of cisplatin and PRIMA-1 MET produced a significantly smaller average tumor volume of 202 mm 3 for the lower dose of cisplatin and 277 mm 3 for the higher dose ( Figure 5 ). The antitumor effect of the combined treatment was statistically significant for the lower dose of cisplatin at P ¼ 0.03, and P ¼ 0.07 for the higher dose as compared to controltreated mice.
Induction of mutant p53 by chemotherapeutic drugs
Since our previous studies have suggested that the efficacy of PRIMA-1 depends on the levels of mutant p53 (Bykov et al., 2002a) , one possible mechanism for the synergy between PRIMA-1 MET and DNA-damaging chemotherapeutic drugs could be induction of mutant p53 protein levels by such drugs. Treatment of H1299-His175 cells expressing His-175 mutant p53 with cisplatin, 5-fluorouracil, and CP-31398 caused an increase in total p53 levels and also induced p53 (Figure 6a ). Treatment with PRIMA-1 MET alone did not significantly induce total p53 levels, nor levels of p53 phosphorylated at Ser15 (Figure 6a ).
To confirm that the response to PRIMA-1 MET is dependent on mutant p53 levels, we examined mutant p53 protein levels before and after PRIMA-1 MET treatment of H1299-His175 cells. Immunostaining and FACS analysis of untreated H1299-His175 cells revealed a heterogeneous pattern of mutant p53 expression, with some cells expressing relatively low levels and other cells expressing higher levels of mutant p53 (Figure 6b ). We cultured H1299-His175 cells in the presence of PRIMA-1 MET for four days, then washed out the reagent and continued culturing. After four days, cells were analysed for mutant p53 expression by immunostaining and FACS. We found that PRIMA-1 MET treatment resulted in clear shift of the p53 expression profile towards cells with lower levels of mutant p53 (Figure 6b) . In other words, PRIMA-1 MET caused a selective elimination of cells expressing high levels of mutant p53, while cells expressing lower levels survived. Hence, cells expressing high levels of mutant p53 are more sensitive to PRIMA-1 MET , confirming that synergy between PRIMA-1 MET and cisplatin may occur through induction of mutant p53 levels by cisplatin.
Discussion
Studies in animal models have shown that disruption of the p53 pathway increases tumor resistance to DNAdamaging chemotherapeutic agents (Schmitt, 2003) . Likewise, several clinical studies have indicated that anticancer drugs preferentially target wild-type p53-carrying breast tumors (Bergh et al., 1995; O'Connor et al., 1997; Weinstein et al., 1997; Borresen-Dale, 2003) . This is probably because wild-type p53-dependent apoptosis induced by commonly used chemotherapeutic drugs is a critical mechanism for elimination of tumor cells in vivo. It is therefore of great importance to identify novel therapeutic strategies for targeting mutant p53-carrying tumors. Recent studies have identified small molecules that reactivate mutant p53 and induce apoptosis in tumor cells. Such molecules represent leads for the development of novel anticancer drugs that could improve clinical outcome. In a screen for more active analogs of PRIMA-1, we have found that PRIMA-1 MET , a methylated version of the original molecule, is more active and specific towards mutant p53-expressing cells based on several assays, including cell proliferation and caspase activation assays.
The ability of novel drugs to reactivate mutant p53 may also be exploited for combination therapy with currently used chemotherapeutic drugs that show preference for wild-type p53-carrying tumors. To test this idea, we treated tumor cells with chemotherapeutic drugs alone or in combination of PRIMA-1 MET and assessed possible synergy using a cell proliferation assay. We found a significant synergistic effect between PRIMA-1 MET and several chemotherapeutic drugs, including cisplatin, adriamycin, and camptothecin, as well as the compound CP-31398 that was reported to rescue mutant p53 conformation and function (Foster et al., 1999) . We also examined synergy between PRIMA-1 MET and cisplatin using other methods to obtain a quantitative assessment of cell death, caspase activation, induction of Bax and PUMA expression, and ability to form colonies. The fact that p53 null cells were more sensitive to cisplatin treatment than His175 mutant p53-expressing cells in some assays could be due to gain-of-function properties of mutant p53 in agreement with previously published data (Matas et al., 2001) . Most importantly, we observed synergy between PRIMA-1 MET and cisplatin in vivo upon systemic administration of suboptimal concentrations of both drugs. The observed synergistic effect was in most cases dependent on mutant p53 expression, consistent with the notion that restoration of wild-type p53 conformation and function should render tumor cells more sensitive to chemotherapeutic drugs that eliminate tumor cells mainly through p53-dependent apoptosis. However, we also consider the possibility that treatment with chemotherapeutic drugs may potentiate the effect of PRIMA-1 MET . Our previous studies indicated that tumor cells expressing high levels of mutant p53 are more sensitive to PRIMA-1 (Bykov et al., 2002a) . Even though mutant p53 is often expressed at relatively high levels in tumor cells, treatment with DNA-damaging drugs like cisplatin could presumably result in a further induction of mutant p53 levels through increased p53 phosphorylation or other types of post-translational modifications. We found a strong synergistic effect between PRIMA-1 MET and compounds that induce DNA damage, for example, cisplatin. Interestingly, CP-31398 that was shown to induce p53 levels through inhibition of p53 ubiquitination (Wang et al., 2003) induced mutant p53 levels and phosphorylation of p53 at Ser15 in H1299-His175 cells and showed synergy with PRIMA-1 MET in mutant p53-expressing cells. Indeed, we found that the DNAdamaging drugs cisplatin and 5-fluorouracil caused elevated levels of mutant p53 and increased p53 Ser15 phosphorylation in tumor cells, presumably enhancing their sensitivity to PRIMA-1 MET treatment. Although we observed an association between Ser15 phosphorylation and p53 protein stability, it is possible that phosphorylation at different site(s), p53 acetylation, or even other post-translational modifications of p53 are responsible for the observed increase in the levels of mutant p53 in response to DNA-damaging chemotherapeutic drugs. These findings suggest that PRIMA-1 MET may synergize with any drug or agent that enhances mutant p53 levels; for instance, gamma irradiation or inhibitors of mutant p53 degradation, for example, proteasome inhibitors.
In most cases, the synergy between PRIMA-1 MET and chemotherapeutic drugs was dependent on mutant p53. However, we also observed synergy between PRIMA-1 MET and camptothecin or vinblastin in p53 null HCT116 cells, and PRIMA-1 MET acted synergistically with cisplatin also in H1299 cells lacking p53 in our colony formation assay. This is most likely due to the fact that both PRIMA-1 MET and cisplatin have p53-independent effects. Cisplatin has been shown to induce p73-dependent apoptosis (Irwin et al., 2003) . The p53-independent synergy was less significant than the mutant p53-dependent synergy, and appeared only in the long-term colony formation assay but not in our short-term assays (WST-1 and FACS). Further studies are required to elucidate the molecular mechanism behind the synergy in p53 null cells. In contrast, we did not find any synergistic effect between PRIMA-1 MET and chemotherapeutic drugs in cells expressing wildtype p53. We cannot rule out that the lack of synergy in wild-type p53-expressing cells is due to low levels of p53 in these cells, although we have not seen any correlation between levels of wild-type p53 expression and sensitivity to PRIMA-1. Wild-type p53-expressing cells are relatively insensitive to PRIMA-1 regardless of wildtype p53 levels (Bykov et al., 2002a ).
Our results demonstrate that the combination of currently used chemotherapeutic drugs and the mutant p53-reactivating compound PRIMA-1 MET may act synergistically to trigger tumor cell apoptosis. This represents a novel principle for cancer therapy based on already existing anticancer drugs. This strategy raises hopes for more efficient cancer treatment, and also suggests that unwanted side effects of currently used chemotherapeutic drugs can be reduced by using lower doses of these drugs in combination with novel anticancer drugs based on the PRIMA-1 scaffold.
Materials and methods

Cells, kits, and antibodies
The human Saos-2 osteosarcoma and H1299 lung adenocarcinoma cell lines are p53 null. The sublines Saos-2-His273 and H1299-His175 carry the indicated tetracycline-regulated mutant p53 expression constructs (Tet-Off). Human HCT116 colon carcinoma cells carry wild-type p53 (p53 þ / þ ) and the isogenic HCT116 (p53À/À) cells are p53 null. SW480 colon carcinoma cells express endogenous His273 mutant p53. CaspaTag TM Pan Fluorescein Caspase (VAD) activity kit was from Intergen (Oxford, UK), carboxyfluorescein (FAM)-labeled caspase inhibitor FAM-DEVD-FMK was obtained from Immunohistochemistry Technologies (Bloomington, MN, USA), polyclonal rabbit anti-p53 and anti-Bax antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA, USA), rabbit polyclonal anti-PUMA antibodies were from Abcam (Cambridge, UK), and FITC-conjugated anti-rabbit Ig was from Vector Laboratories (Burlingame, CA, USA).
WST-1 assays
Cells were plated in 96-well plates at a density of 3000 cells per well in 100 ml medium, cultured overnight, and treated according to the applied protocol. After 96 h, WST-1 cell proliferation reagent (Roche, Basel, Switzerland) was added and samples were incubated at 371C for 1-2 h and absorbance measured at 490 nm.
Combination treatment and criteria for synergy
Cells were grown in 96-well plates and treated with PRIMA-1 for 8 h. The cells were then treated with one of the following drugs or compounds: cisplatin, 5-fluorouracil, adriamycin, camptothecin, paclitaxel, vinblastin and CP-31398. Two drugs or compounds were considered to act synergistically when growth suppression induced by the combined treatment was greater than the sum of the growth suppression induced by each drug or compound alone (see Supplementary Information for details).
Flow cytometry
Samples were analysed on a FACSCalibur flow cytometer (Becton Dickinson Immunocytometry Systems, San Jose, CA, USA). The Kolmogorov-Smirnov (KS) statistic (see http:// www.physics.csbsju.edu/stats/KS-test.html), expressed as a D value, was used to compare binding of antibodies to control and treated cell populations. The D value shows the maximum difference in cumulative fractions between two data sets. The higher the D value, the greater is the difference between cellular populations. For DNA fragmentation assays, cells were fixed, treated with propidium iodide and analysed on FACSCalibur according to standard procedures. For internal antigens, cells were fixed in 57% ethanol, stained with primary and secondary antibodies according to standard procedures. For detection of active caspase-3-positive cells, H1299 and H1299-His175 were plated in six-well plates at the initial density of 10 000 cells/cm 2 , cultured overnight, and treated with PRIMA-1 or PRIMA-1 MET . After 24 h, cells were harvested by trypsinization, and labeled with FLICA according to the manufacturer's recommendations. Samples were analysed on FACSCalibur.
Colony formation assays
Cells were plated in 12-well plates at the initial density of 10 000 cells/cm 2 , incubated overnight, and treated with PRI-MA-1 MET . After 10 h, cells were treated with cisplatin for 72 h. Cells were harvested by trypsinization and plated in flasks at a density of 5 cells/cm 2 (counted from the initial cell number). Cells were left to grow for 10 days, then fixed with methanol, stained with Giemsa stain (Sigma-Aldrich, St Louis, MO, USA) and colonies were counted.
In vivo studies
All in vivo studies were approved by the local animal ethical committee in Stockholm, Sweden, and animal care was in accordance with institutional guidelines. The maximal allowed volume of tumor xenografts was 1.5 cm ) in one flank. Xenografts were allowed to grow for 11 days up to the formation of palpable tumors. Control animals received i.p. injections of PBS once daily for 10 days; two groups received i.p. injections of 0.25 or 1 mg/kg of cisplatin (Platinol) once every three days with a total of three injections per mouse; one group from day 2 received i.p. injections of 100 mg/kg of PRIMA-1 MET once daily for nine days; two groups received combined treatment with either 0.25 or 1 mg/kg of cisplatin and 100 mg/kg of PRIMA-1 MET as above. The tumor volumes were measured by caliper.
Data analysis
Data were analysed by Microcal Origin statistical software. Flow cytometry data were analysed by WinMDI 2.8 and by BD Cell Quest Pro FACS software.
